Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients
Joint Authors
Hilal, Dua S.
al-Jundi, Dina M.
Sabri, Nisrin M.
Abu al-Nasr, Muhammad
Source
Journal of the Egyptian National Cancer Institute
Issue
Vol. 30, Issue 4 (31 Dec. 2018), pp.125-131, 7 p.
Publisher
Cairo University National Cancer Institute
Publication Date
2018-12-31
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Cancer immunotherapy targeting programmed cell death-1/programmed cell death ligand-1 (PD-1/PDL1) pathway has shown promising results in treatment of non-small cell lung cancer (NSCLC) patients.
T cells play a major role in tumor-associated immune response.
This study aimed to investigate PD-L1 expression alone and combined with CD8 tumor infiltrating lymphocytes (TILs) density in relation to clinicopathologic parameters and survival in NSCLC patients.
Immunohistochemical analysis was used to evaluate PD-L1 expression and CD8 TILs density in 55 NSCLC patients.
PD-L1 immunopositivity was detected in 36 (65.5%) of NSCLC cases.
PD-L1 expression was significantly related to high tumor grade (p value = 0.038) and low CD8 TILs density (p value = 0.004), whereas no significant relations were detected between PD-L1 expression and tumor stage (p value = 0.121), overall survival (OS) (p value = 0.428) and progression-free survival (PFS) (p value = 0.439).
Among PD-L1/CD8 TILs density groups, PD-L1+/CD8Low group was significantly associated with high tumor grade compared to PD-L1/ CD8high group (pairwise p = 0.016).
PD-L1+/CD8Low group was significantly related to advanced tumor stage compared to PD-L1+/CD8high and PD-L1/CD8Low groups (pairwise p = 0.001 and 0.013 respectively).
PD-L1/CD8high group exhibited the best OS and PFS whereas PD-L1+/CD8low group had the poorest OS and PFS (p value = 0.032 and 0.001 respectively).
Assessment of PD-L1 combined with CD8 TILs density, instead of PD-L1 alone, suggested important prognostic relevance in NSCLC patients.
American Psychological Association (APA)
al-Jundi, Dina M.& Sabri, Nisrin M.& Hilal, Dua S.& Abu al-Nasr, Muhammad. 2018. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. Journal of the Egyptian National Cancer Institute،Vol. 30, no. 4, pp.125-131.
https://search.emarefa.net/detail/BIM-874659
Modern Language Association (MLA)
al-Jundi, Dina M.…[et al.]. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. Journal of the Egyptian National Cancer Institute Vol. 30, no. 4 (Dec. 2018), pp.125-131.
https://search.emarefa.net/detail/BIM-874659
American Medical Association (AMA)
al-Jundi, Dina M.& Sabri, Nisrin M.& Hilal, Dua S.& Abu al-Nasr, Muhammad. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. Journal of the Egyptian National Cancer Institute. 2018. Vol. 30, no. 4, pp.125-131.
https://search.emarefa.net/detail/BIM-874659
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 131
Record ID
BIM-874659